Phase 1 N=45 Randomized Treatment

Effect of Platelet Rich Plasma and Keratinocyte Suspensions on Wound Healing

Skin Graft

Bottom Line

View on ClinicalTrials.gov: NCT00856934 ↗

Enrolled (actual)

Serious AEs

—

Results posted

Mar 2009

Primary outcome: Primary: Complete Wound Healing — 13.9; 7.2; 5.7 Days — p=0.05

Study Design & Population

Study type: Interventional
Phase: Phase 1
Interventions: Autologous Platelet Rich Plasma (Biological); Keratinocyte suspension (Biological); Standard dressings (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Centre Hospitalier Universitaire Vaudois
Primary completion: Mar 2006

Outcome Measures

Outcome	Result	p-value
PRIMARY Complete Wound Healing	13.9; 7.2; 5.7	0.05
SECONDARY Pain	7.2; 1.5; 0.4	0.05

Summary

This prospective randomized trial evaluated the impact of autologous keratinocytes suspended in platelet concentrates on healing skin graft donor site wounds. It was hypothesized that the treatment would speed and improve wound healing.

Eligibility Criteria

Inclusion Criteria

Skin graft donor sites total surface < 15% BSA
Skin graft donor site size: 0.2mm deep, 30 to 40 cm2 surface area

Exclusion Criteria

Patients treated with immunosuppressors
Patients treated with corticoids
Patients suffering from terminal renal insufficiency
Patients suffering from severe peripheral arteriopathy

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00856934). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.